Cardium Therapeutics reported today that researchers at the University of Cincinnati on a NIH funded pre clinic study able to potentiate Mesenchymal Stem Cells to accelerate bone marrow stem cell mobilization via paracrine activation to promote myocardial Repair.
The study was published in the American Heart Association’s journal Circulation Research (Circ Res. 2008; 103(11): 1300-1308).
The investigators reported that mesenchymal stem cells (MSCs) can be potentiated by introducing Ad5IGF-1 into the cells while they are being processed outside of the body or ex vivo. Upon reintroduction into the body, these Ad5IGF-1 activated stem cells substantially reduced heart attack related tissue damage (infarct size), caused extensive angiomyogenesis, and improved left ventricular ejection fraction and fractional shortening.
MSCs not treated with Ad5IGF-1 had significantly less therapeutic effect in this preclinical model of heart attack.
The findings indicates that mesenchymal stem cells, which are processed ex vivo before reintroduction into the body, tend to loose certain capabilities required for effective binding and retention within injured heart tissue such as that occurring after a heart attack.
According Christopher J. Reinhard, Cardium’s Chief Executive Officer Cardium, their company has been developing a portfolio of innovative DNA-based growth factor therapeutics for cardiovascular and related applications. Their Corgentin (Ad5IGF-1) product candidate is designed to lessen tissue injury and promote myocardial repair and restoration following a heart attack.
This new study provides important insights into the potential synergies obtainable when mesenchymal stem cells are potentiated ex vivo by Ad5IGF-1 and suggest that Corgentin may be able to substantially improve stem cell approaches to the treatment of important disease conditions such as a heart attack and other cardiovascular indications including based on the use of stem cells.
The full article can be accessed at www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2640486. [www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2640486]
Source: Cardium Therapeutics